Receptor Interactions Involved in Adenoviral-Mediated Gene Delivery after Systemic Administration in Non-Human Primates

Human Gene Therapy

Volumn 14, Issue 17, 2003, Pages 1595-1604

  Smith, Theodore A G ^a   Iverson, William O ^a   Sherer, Alfred D ^a   Markovits, Judit E ^a   Lyons, Russette M ^a   Kaleko, Michael ^b   Stevenson, Susan C ^a   Idamakanti, Neeraja ^a   Marshall Neff, Jennifer ^a   Rollence, Michele L ^a   Wright, Patrick ^a   Kaloss, Michele ^a   King, Laura ^a   Mech, Christine ^a   Dinges, Lisa ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Advanced Vision Therapies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; AMINO ACID; ASPARTATE AMINOTRANSFERASE; CAPSID PROTEIN; INTEGRIN; INTERLEUKIN 6; RECEPTOR PROTEIN; VIRUS RECEPTOR; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SURFACE; CONTROLLED STUDY; COXSACKIE VIRUS; DRUG DISTRIBUTION; ENZYME BLOOD LEVEL; FIBER; GENE DELIVERY SYSTEM; GENE MUTATION; IN VIVO STUDY; KIDNEY; LIVER; LUNG; MALE; MOUSE STRAIN; NONHUMAN; PLANT GROWTH; PRIMATE; SPECIES DIFFERENTIATION; SPLEEN;

ADENOVIRIDAE; ANIMALS; CAPSID PROTEINS; CELL MEMBRANE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHAV; INTERLEUKIN-6; LIVER; MACACA FASCICULARIS; MALE; MICE; MUTATION; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TISSUE DISTRIBUTION; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; ANIMALIA; COXSACKIEVIRUS; MACACA FASCICULARIS; PRIMATES;

EID: 10744221060     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303403322542248     Document Type: Article

References (34)

1. ALEMANY, R., and CURIEL, D.T. (2001). CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther. 8, 1347-1353.
2. ALEMANY, R., SUZUKI, K., and CURIEL, D.T. (2000). Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 81, 2605-2609.
3. ANDREWS, J.L., SHIRLEY, P.S., IVERSON, W.O., SHERER, A.D., MARKOVITS, J.E., KING, L., LYONS, R.M., KALEKO, M., and CONNELLY, S. (2002). Evaluation of the duration of human factor VIII expression in nonhuman primates after systemic delivery of an adenoviral vector. Hum. Gene Ther. 13, 1331-1336.
4. BERGELSON, J.M., CUNNINGHAM, J.A., DROGUETT, G., KURTJONES, E.A., KRITHIVAS, A., HONG, J.S., HORWITZ, M.S., CROWELL, R.L., and FINBERG, R.W. (1997). Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323.
5. BRANN, T., KAYDA, D., LYONS, R.M., SHIRLEY, P., ROY, S., KALEKO, M., and SMITH, T. (1999). Adenoviral vector-mediated expression of physiologic levels of human factor VIII in nonhuman primates. Hum. Gene Ther. 10, 2999-3011.
6. CHIRMULE, N., PROPERT, K., MAGOSIN, S., QIAN, Y., QIAN, R., and WILSON, J. (1999). Immune responses to adenovirus and adenoassociated virus in humans. Gene Ther. 6, 1574-1583.
7. COHEN, C.J., SHIEH, J.T., PICKLES, R.J., OKEGAWA, T., HSIEH, J.T., and BERGELSON, J.M. (2001). The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc. Natl. Acad. Sci. U.S.A. 98, 15191-15196.
8. CONNELLY, S., ANDREWS, J.L., GALLO, A.M., KAYDA, D.B., QIAN, J., HOYER, L., KADAN, M.J., GORZIGLIA, M.I., TRAPNELL, B.C., MCCLELLAND, A., and KALEKO, M. (1998). Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 91, 3273-3281.
9. DECHECCHI, M.C., TAMANINI, A., BONIZZATO, A., and CABRINI, G. (2000). Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 268, 382-390.
10. DECHECCHI, M.C., MELOTTI, P., BONIZZATO, A., SANTACATTERINA, M., CHILOSI, M., and CABRINI, G. (2001). Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J. Virol. 75, 8772-8780.
11. EIZ, B., ADRIAN, T., and PRING-AKERBLOM, P. (1997). Recombinant fibre proteins of human adenoviruses Ad9, Ad15 and Ad19: Localization of the haemagglutination properties and the type-specific determinant. Res. Virol. 148, 5-10.
12. FECHNER, H., HAACK, A., WANG, H., WANG, X., EIZEMA, K., PAUSCHINGER, M., SCHOEMAKER, R., VEGHEL, R., HOUTSMULLER, A., SCHULTHEISS, H.P., LAMERS, J., and POLLER, W. (1999). Expression of coxsackie adenovirus receptor and alpha v-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther. 6, 1520-1535.
13. GREEN, N.K., and SEYMOUR, L.W. (2002). Adenoviral vectors: Systemic delivery and tumor targeting. Cancer Gene Ther. 9, 1036-1042.
14. HAYASHI, K., HAYASHI, M., JALKANEN, M., FIRESTONE, J.H., TRELSTAD, R.L., and BERNFIELD, M. (1987). Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues. A light and electron microscopic study. J. Histochem. Cytochem. 35, 1079-1088.
15. HILEMAN, R.E., FROMM, J.R., WEILER, J.M., and LINHARDT, R.J. (1998). Glycosaminoglycan-protein interactions: Definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 20, 156-167.
16. JAKUBCZAK, J.L., ROLLENCE, M.L., STEWART, D.A., JAFARI, J.D., VON SEGGERN, D.J., NEMEROW, G.R., STEVENSON, S.C., and HALLENBECK, P.L. (2001). Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells. J. Virol. 75, 2972-2981.
17. rd Annual Meeting of the American Association of Cancer Research. San Francisco, CA April 6, 2002.
18. LEISSNER, P., LEGRAND, V., SCHLESINGER, Y., HADJI, D.A., VAN RAAIJ, M., CUSACK, S., PAVIRANI, A., and MEHTALI, M. (2001). Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism. Gene Ther. 8, 49-57.
19. LOZIER, J.N., METZGER, M.E., DONAHUE, R.E., and MORGAN, R.A. (1999). Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity. Blood 94, 3968-3975.
20. LOZIER, J.N., CSAKO, G., MONDORO, T.H., KRIZEK, D.M., METZGER, M.E., COSTELLO, R., VOSTAL, J.G., RICK, M.E., DONAHUE, R.E., and MORGAN, R.A. (2002). Toxicity of a first-generation adenoviral vector in rhesus macaques. Hum. Gene Ther. 13, 113-124.
21. MEI, Y.F., and WADELL, G. (1996). Epitopes and hemagglutination binding domain on subgenus B:2 adenovirus fibers. J. Virol. 70, 3688-3697.
22. MITTEREDER, N., YEI, S., BACHURSKI, C., CUPPOLETTI, J., WHITSETT, J.A., TOLSTOSHEV, P., and TRAPNELL, B.C. (1994). Evaluation of the efficacy and safety of in vitro, adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA. Hum. Gene Ther. 5, 717-729.
23. MITTEREDER, N., MARCH, K.L., and TRAPNELL, B.C. (1996). Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70, 7498-7509.
24. MIZUGUCHI, H., KOIZUMI, N., HOSONO, T., ISHII-WATABE, A., UCHIDA, E., UTOGUCHI, N., WATANABE, Y., and HAYAKAWA, T. (2002). CAR-or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Ther. 9, 769-776.
25. MORRAL, N., O'NEAL, W.K., RICE, K., LELAND, M.M., PIEDRA, P.A., AGUILAR-CORDOVA, E., CAREY, K.D., BEAUDET, A.L., and LANGSTON, C. (2002). Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum. Gene Ther. 13, 143-154.
26. REID, T., GALANIS, E., ABBRUZZESE, J., SZE, D., WEIN, L.M., ANDREWS, J., RANDLEV, B., HEISE, C., UPRICHARD, M., HATFIELD, M., ROME, L., RUBIN, L, and KIRN, D. (2002). Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Res. 62, 6070-6079.
27. SCHNELL, M.A., ZHANG, Y., TAZELAAR, J., GAO, G.P., YU, Q.C., QIAN, R., CHEN, S.J., VARNAVSKI, A.N., LECLAIR, C., RAPER, S.E., and WILSON, J.M. (2001). Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol. Ther. 3, 708-722.
28. SMITH, T.A., MEHAFFEY, M.G., KAYDA, D.B., SAUNDERS, J.M., YEI, S., TRAPNELL, B.C., MCCLELLAND, A., and KALEKO, M. (1993). Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat. Genet. 5, 397-402.
29. SMITH, T.A., IDAMAKANTI, N., KYLEFJORD, H., ROLLENCE, M., KING, L., KALOSS, M., KALEKO, M., and STEVENSON, S.C. (2002). In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Mol. Ther. 5, 770-779.
30. SMITH, T.A., IDAMAKANTI, N., ROLLENCE, M., MARSHALLNEFF, J., KIM, J., NEMEROW, G.R., KALEKO, M., and STEVENSON, S.C. (2003). The adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum. Gene Ther. 14, 777-787.
31. VLACHAKI, M.T., HERNANDEZ-GARCIA, A., ITTMANN, M., CHHIKARA, M., AGUILAR, L.K., ZHU, X., THE, B.S., BUTLER, E.B., WOO, S., THOMPSON, T.C., BARRERA-SALDANA, H., and AGUILAR-CORDOVA, E. (2002). Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol. Ther. 6, 342-348.
32. WALTERS, R.W., GRUNST, T., BERGELSON, J.M., FINBERG, R.W., WELSH, M.J., and ZABNER, J. (1999). Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J. Biol. Chem. 274, 10219-10226.
33. WICKHAM, T.J., MATHIAS, P., CHERESH, D.A., and NEMEROW, G.R. (1993). Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73, 309-319.
34. ZHANG, Y., CHIRMULE, N., GAO, G.P., QIAN, R., CROYLE, M., JOSHI, B., TAZELAAR, J., and WILSON, J.M. (2001). Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol. Ther. 3, 697-707.